Phase I Study of Inavolisib in PIK3CA-Mutant Solid Tumors and Breast Cancer
A Phase I study is evaluating inavolisib's safety and pharmacokinetics in PIK3CA-mutant solid tumors, including breast cancer.
Indication
Clinical and regulatory intelligence for PIK3CA-mutant Breast Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.